Stocks
enGene Therapeutics Inc.ENGNW
NASDAQHealthcareBiotechnology$0.19
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing non-viral gene therapies, with a lead candidate targeting bladder cancer. Its platform uses polymer-based delivery to enable localized gene transfer, and investors track it for its potential to address unmet needs in oncology.
52W Range: $0.15-$0.19
Congressional Interest in enGene Therapeutics Inc. (ENGNW)
No congressional trades have been disclosed for enGene Therapeutics Inc. (ENGNW) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ENGNW?
No congressional trades found for this stock.